This opportunity is no longer accepting applications.
grant PAR-22-200

Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)

This grant opportunity aims to support the creation and development of medications to prevent and treat opioid and psychostimulant use disorders, as well as overdoses. It involves two phases through the UG3/UH3 Phase Innovation Awards Cooperative Agreement. The first phase (UG3) lasts for two years, where projects must meet certain milestones to qualify for the second phase (UH3), which provid…

The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid and/or psychostimulant use disorders and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a pr…

Funding Source

Agency: National Institutes of Health
Sub-agency: National Institute on Drug Abuse
Program: SBIR

Awards & funding

Award Ceiling: $3M
Award Amount: $3M

Dates

Opportunity Released: September 1, 2022
Open for Submission: September 1, 2022
Submission Deadline: September 1, 2025
Application Window Closes: September 1, 2025

Supporting links

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.